KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

被引：2
|
作者：
Shariat, S. F. [1 ]
Steinberg, G. [2 ]
Kamat, A. M. [3 ]
Shore, N. D. [4 ]
Alanee, S. [5 ,6 ]
Nishiyama, H. [7 ]
Nam, K. [8 ]
Godwin, J. L. [8 ]
Kapadia, E. [8 ]
Hahn, N. [9 ]
机构：
[1] Med Univ Vienna, Urol, Vienna, Austria
[2] NYU Langone Hlth, Urol, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA
[4] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[5] Michigan State Univ, Urol, Detroit, MI USA
[6] Michigan State Univ, Detroit Med Ctr, Detroit, MI USA
[7] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[8] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[9] Johns Hopkins Univ, Sch Med, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
718TiP
引用
收藏
页码：S723 / S723
页数：1
相关论文
共 50 条
  • [21] SINGLE INSTILLATION OF MITOMYCIN C (MMC) PLUS BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Weiss, Brian
    Wein, Alan
    Malkowicz, S. Bruce
    Guzzo, Thomas
    [J]. JOURNAL OF UROLOGY, 2015, 193 (04): : E294 - E294
  • [22] The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
    Hofbauer, Sebastian L.
    Shariat, Shahrokh F.
    Chade, Daher C.
    Sarkis, Alvaro S.
    Ribeiro-Filho, Leopoldo A.
    Nahas, Willian C.
    Klatte, Tobias
    [J]. UROLOGIA INTERNATIONALIS, 2016, 96 (01) : 46 - 50
  • [23] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [24] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [25] The Effectiveness of Bacillus Calmette-Guerin (BCG) Maintenance Treatment in Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Kim, B.
    Ha, J.
    Park, C.
    Kim, C.
    [J]. UROLOGY, 2012, 80 (03) : S215 - S216
  • [26] Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Gu ′erin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC).
    Shore, Neal D.
    Gupta, Shilpa
    Kulkarni, Girish S.
    Necchi, Andrea
    Dave, Hema Kishore
    Kapadia, Ekta
    Zhao, Qing
    Kamat, Ashish M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
    Gaylis, Franklin D.
    Emond, Bruno
    Manceur, Ameur M.
    Tardif-Samson, Anabelle
    Morrison, Laura
    Pilon, Dominic
    Lefebvre, Patrick
    Ellis, Lorie
    Balaji, Hiremagalur parthasarathy
    Ireland, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Real-world treatment patterns among patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin (BCG)
    Kumar, Neela
    Balaji, Hiremagalur Parthasarathy
    Emond, Bruno
    Manceur, Ameur M.
    Ghelerter, Isabelle
    Pilon, Dominic
    Lefebvre, Patrick
    Imran, Nida Shafaat
    Ellis, Lorie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 404 - 404
  • [30] BLADDER BIOPSY AT 3 MONTHS POST-BACILLUS CALMETTE-GUERIN (BCG) INDUCTION FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) IS NOT CORRELATED WITH ONCOLOGICAL OUTCOMES
    Zhang, Mimi
    Godoy, Guilherme
    Lerner, Seth
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E731 - E731
12345